Ultragenyx Pharma v. Navinta 2:26-cv-03585: Litigation Summary, Claims, and Business Impact Executive summary: The case Ultragenyx Pharmaceutical Inc. v. Navinta […]

SHIONOGI v. LUPIN (2:26-cv-06218): Litigation Summary, Patent Estate Impact, and Generic Launch Risk Shionogi Inc. v. Lupin Limited, case number

A patent expiry for a blockbuster drug is not a legal event. It’s a commercial trigger. The twelve months before

The biosimilar wave was supposed to be simple. Blockbuster biologics lose patent protection, cheaper copies enter the market, prices collapse,

The assumption is logical: if a tool costs nothing, you save money using it. That arithmetic breaks down badly when

Every year, generic pharmaceutical companies write off hundreds of millions of dollars on programs that were commercially viable on paper

The pharmaceutical industry loses about 80% of a brand’s revenue within twelve months of generic entry. For a blockbuster generating

When AbbVie watched its first Humira biosimilar land on the US market in January 2023, the company had already spent

Branded generics — off-patent drugs sold under a proprietary name rather than an INN — are a $280 billion global